Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure
Authors
Silvio E. Inzucchi
Julia Kuder (ORCID: https://orcid.org/0000-0002-7099-1538)
Christian T. Ruff (ORCID: https://orcid.org/0000-0002-4712-3206)
John E. McGinty
Andrzej Przybylski (ORCID: https://orcid.org/0000-0002-8136-7589)
John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
National Center for Advancing Translational Sciences
Duke Clinical Research Institute
Daiichi Sankyo Europe
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure
Silvio E. Inzucchi, Julia Kuder, Christian T. Ruff, John E. McGinty et al.
Citations
19 citations
Journal
Circulation
Topics
Diabetes Treatment and Management
Field-Weighted Citation Impact (FWCI)
24.60
article
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure
Silvio E. Inzucchi, Julia Kuder, Christian T. Ruff, John E. McGinty, Andrzej Przybylski, John J.V. McMurray, Eileen O’Meara, Marc S. Sabatine, Joseph L. Izzo, Jarosław Dróżdż, David D. Berg, Jan Bělohlávek, Abby L. Cange, Siddharth M. Patel, T. Drasnar, Andrea Bellavia, Prakash Krishnan, Modele O. Ogunniyi, Paul M. Haller, Subodh Verma, Michelle L. O’Donoghue, Michael G. Palazzolo, Sabina A. Murphy, Béla Péter Merkely, Balázs Sármán, Akshay S. Desai, Stephen D. Wiviott, Angel Mulkay
article en
19 citations
Abstract
No abstract available for this paper.
Publication Tag
CirculationVol. 152(20)
Institutions
Semmelweis University (HU), Holy Name Medical Center (US), Brigham and Women's Hospital (US), St. Michael's Hospital (CA), Grady Memorial Hospital (US), Harvard University (US), University of British Columbia (CA), Emory University (US), Universität Hamburg (DE), Charles University (CZ), Erie County Medical Center (US), Montreal Heart Institute (CA), British Heart Foundation (GB), Yale University (US), Wroclaw Medical University (PL), Grady Health System (US), University Medical Center Hamburg-Eppendorf (DE), Medical University of Lodz (PL), Uzsoki Hospital (HU), Ovus (Czechia) (CZ), Reid Health (US), St. Paul's Hospital (CA), AstraZeneca (Spain) (ES), CM Hospital (KR), Thrombolysis in Myocardial Infarction Study Group (US), General University Hospital in Prague (CZ), Université de Montréal (CA), University of Glasgow (GB), University of Rzeszów (PL)
Funders
Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Brigham and Women's Hospital, Alnylam Pharmaceuticals, iRhythm Technologies, Medpace, Harvard Catalyst, Boston Scientific Corporation, Regeneron Pharmaceuticals, Deutsches Zentrum für Herz-Kreislaufforschung, Ionis Pharmaceuticals, Amarin Corporation, Cytokinetics, Medicines Company, Kowa Company, Verily Life Sciences, Zora Biosciences, Abiomed, ARCA Biopharma, University of Glasgow, Deutsche Forschungsgemeinschaft, Daiichi-Sankyo, Novo Nordisk, Deutsche Herzstiftung, Servier, Institut de Cardiologie de Montréal, HLS Therapeutics, Intas Pharmaceuticals, National Institutes of Health, American Regent, Canadian Institutes of Health Research, Defense Acquisition Program Administration, National Heart, Lung, and Blood Institute, Janssen Research and Development, National Center for Advancing Translational Sciences, Duke Clinical Research Institute, Daiichi Sankyo Europe